CytomX Therapeutics CTMX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's investing cash flow?
- CytomX Therapeutics (CTMX) reported investing cash flow of -$192.78M in Q1 2026.
- How has CytomX Therapeutics's investing cash flow changed year-over-year?
- CytomX Therapeutics's investing cash flow decreased by 730.1% year-over-year, from $30.6M to -$192.78M.
- What is the long-term trend for CytomX Therapeutics's investing cash flow?
- Over 2 years (2022 to 2025), CytomX Therapeutics's investing cash flow has grown at a -21.7% compound annual growth rate (CAGR), from $98.26M to -$60.18M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.